Amreen Dinani is a Gastroenterology physician. OpenAlex indexes 95 publications with 707 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
17 E 102nd St
New York, NY 100295204
Telephone
212-241-7270Provider last certified this registry record 29 Nov 2022.
Clinical trials
- Androgens and NAFLD Longitudinal Cohort Study
Sponsor: University of California, San Francisco
- Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202524 payments$69,061openpaymentsdata.cms.gov ↗
- Madrigal PharmaceuticalsProgram year202542 payments$57,461openpaymentsdata.cms.gov ↗
- Novo Nordisk ASProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
59.2%Osmotic Laxative30.3%Gavilyte-G78%Peg-3350 And Electrolytes22%Part D≥58 patientsRifamycin Antibacterial16.5%Xifaxan100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
40.8%Loop diuretic13.5%Furosemide100%Part D≥15 patientsAldosterone antagonist (MRA)12.7%Spironolactone100%Part D≥16 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Journal of the American College of Cardiology
2025 - Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis
Clinical Gastroenterology and Hepatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”